Of note, this new entity is distinct from IDH-wildtype astrocytomas harboring one or more of the molecular features TERT promoter mutation, EGFR amplification, gain of entire chromosome 7, or loss of entire chromosome 10, which are diagnosed collectively as Glioblastoma, IDH-wildtype, CNS WHO grade IV with the molecular information (Table 1). Here, IDH2 is linked to astrocytoma (excluding glioblastoma).